Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Characterization of P1 (adenosine) purinoceptors.

Jarvis MF.

Curr Protoc Pharmacol. 2013 Oct 8;62:Unit 1.9.. doi: 10.1002/0471141755.ph0109s62.

PMID:
24510716
2.

P1 (adenosine) purinoceptor assays.

Mustafa SJ, Ansari HR, Abebe W.

Curr Protoc Pharmacol. 2009 Jun;Chapter 4:Unit 4.7. doi: 10.1002/0471141755.ph0407s45.

PMID:
22294395
3.
4.

Endogenous luminal surface adenosine signaling regulates duodenal bicarbonate secretion in rats.

Ham M, Mizumori M, Watanabe C, Wang JH, Inoue T, Nakano T, Guth PH, Engel E, Kaunitz JD, Akiba Y.

J Pharmacol Exp Ther. 2010 Dec;335(3):607-13. doi: 10.1124/jpet.110.171520.

5.

A(1) and A(3) adenosine receptors inhibit LPS-induced hypoxia-inducible factor-1 accumulation in murine astrocytes.

Gessi S, Merighi S, Stefanelli A, Fazzi D, Varani K, Borea PA.

Pharmacol Res. 2013 Oct;76:157-70. doi: 10.1016/j.phrs.2013.08.002.

PMID:
23969284
6.

Antiproliferative effects of selective adenosine receptor agonists and antagonists on human lymphocytes: evidence for receptor-independent mechanisms.

Schiedel AC, Lacher SK, Linnemann C, Knolle PA, Müller CE.

Purinergic Signal. 2013 Sep;9(3):351-65. doi: 10.1007/s11302-013-9354-7.

7.

Changes in purine levels and adenosine receptors in kindled seizures in the rat.

Adén U, O'Connor WT, Berman RF.

Neuroreport. 2004 Jul 19;15(10):1585-9.

PMID:
15232288
8.

Selectivity is species-dependent: Characterization of standard agonists and antagonists at human, rat, and mouse adenosine receptors.

Alnouri MW, Jepards S, Casari A, Schiedel AC, Hinz S, Müller CE.

Purinergic Signal. 2015 Sep;11(3):389-407. doi: 10.1007/s11302-015-9460-9.

9.

Comparative pharmacology of human adenosine receptor subtypes - characterization of stably transfected receptors in CHO cells.

Klotz KN, Hessling J, Hegler J, Owman C, Kull B, Fredholm BB, Lohse MJ.

Naunyn Schmiedebergs Arch Pharmacol. 1998 Jan;357(1):1-9.

PMID:
9459566
10.

Adenosine receptors and their ligands.

Klotz KN.

Naunyn Schmiedebergs Arch Pharmacol. 2000 Nov;362(4-5):382-91. Review.

PMID:
11111832
11.

Expeditious synthesis and biological evaluation of new C-6 1,2,3-triazole adenosine derivatives A1 receptor antagonists or agonists.

Mathew SC, By Y, Berthault A, Virolleaud MA, Carrega L, Chouraqui G, Commeiras L, Condo J, Attolini M, Gaudel-Siri A, Ruf J, Rodriguez J, Parrain JL, Guieu R.

Org Biomol Chem. 2010 Sep 7;8(17):3874-81. doi: 10.1039/c0ob00017e.

PMID:
20617271
12.

Binding of the radioligand [3H]-SCH 58261, a new non-xanthine A2A adenosine receptor antagonist, to rat striatal membranes.

Zocchi C, Ongini E, Ferrara S, Baraldi PG, Dionisotti S.

Br J Pharmacol. 1996 Apr;117(7):1381-6.

14.

New substituted 9-alkylpurines as adenosine receptor ligands.

Camaioni E, Costanzi S, Vittori S, Volpini R, Klotz KN, Cristalli G.

Bioorg Med Chem. 1998 May;6(5):523-33.

PMID:
9629466
15.

Activation of A3 adenosine receptors on human eosinophils elevates intracellular calcium.

Kohno Y, Ji X, Mawhorter SD, Koshiba M, Jacobson KA.

Blood. 1996 Nov 1;88(9):3569-74.

16.

Vascular adenosine receptors; potential clinical applications.

Ho MF, Rose'Meyer RB.

Curr Vasc Pharmacol. 2013 May;11(3):327-37. Review.

PMID:
22724462
17.

G protein-coupled adenosine (P1) and P2Y receptors: ligand design and receptor interactions.

Jacobson KA, Balasubramanian R, Deflorian F, Gao ZG.

Purinergic Signal. 2012 Sep;8(3):419-36. doi: 10.1007/s11302-012-9294-7. Review.

18.

Purinoceptors in the nervous system.

Fredholm BB.

Pharmacol Toxicol. 1995 Apr;76(4):228-39. Review.

PMID:
7617551
19.

1,8-disubstituted xanthine derivatives: synthesis of potent A2B-selective adenosine receptor antagonists.

Hayallah AM, Sandoval-Ramírez J, Reith U, Schobert U, Preiss B, Schumacher B, Daly JW, Müller CE.

J Med Chem. 2002 Mar 28;45(7):1500-10.

PMID:
11906291
20.

Pharmacological modulation of adenosine receptor pathways and inflammatory disorders: the way towards novel therapeutics?

Antonioli L, Fornai M, Colucci R, Tuccori M, Blandizzi C.

Expert Opin Investig Drugs. 2011 Jun;20(6):717-21. doi: 10.1517/13543784.2011.579104. No abstract available.

PMID:
21506907
Items per page

Supplemental Content

Support Center